Abstract: The invention relates to a pharmaceutical composition containing a PLP-dependent enzyme and optionally its cofactor, pyridoxal phosphate (PLP), and/or a phosphate or non-phosphate precursor of PLP, its use as a drug, its production method and a therapeutic treatment method related to it. The pharmaceutical composition comprises erythrocytes and a pharmaceutically acceptable vehicle, the erythrocytes encapsulating the PLP-dependent enzyme. The PLP-dependent enzyme may be methioninase, tyrosine phenol-lyase, tyrosine aminotransferase or cystathionine beta-synthase.

Abstract: Methods and compositions are described herein that inhibit FAK/ATK interactions. Such methods and compositions are useful for inhibiting cell adhesion and cancer metastasis.

Abstract: The present disclosure relates to a novel strain of Lactobacillus fermentum LM1016 (KCCM12468P). The disclosed strain can be useful for treating or preventing cardiovascular diseases, obesity, fatty liver and/or diabetes. The present disclosure also relates to compositions comprising the strain. The compositions can be useful for medicines, health-functional foods, dairy products, fermented products, food additives, animal feeds, etc.

Abstract: Embodiments of the invention involve treating ophthalmology conditions by the topical or oral use of acetylcholinesterase inhibitors. By effectively reducing or eliminating the population of Demodex mites in affected areas and areas where Demodex mites may exist, this treatment achieves a more complete remission of clinical signs and symptoms of the ophthalmological afflictions than any previously described method. Embodiments of the invention are useful for treating ocular afflictions caused by Demodex-induced inflammatory eye conditions, including meibomian gland dysfunction, conjunctivitis, keratoconjunctivitis, hyperemia, blepharitis and dry eye disease.

Abstract: A kit, including: a first solution, a second solution, and a metal mesh. The first solution includes: dulbecco's modified eagle medium (DMEM), 65-95 V/V %; dimethyl sulfoxide (DMSO), 5.5-20 V/V %; ethylene glycol (EG), 3.5-15 V/V %; bovine serum albumin (BSA), 0.5-4 W/V %; sucrose 1-5 W/V %; methylcellulose with a viscosity of 4000 centipoise (cP), 0.05-0.8 W/V %; hetastarch 0.25-0.6 W/V %; and glucose 15-35 W/V %. The second solution includes: DMEM, 65-95 V/V %; DMSO, 5.5-20 V/V %; EG, 8-20 V/V %; BSA, 0.5-4 W/V %; sucrose, 10-20 W/V %; methylcellulose with a viscosity of 4000 centipoise (cP), 0.05-0.8 W/V %; polyvinyl pyrrolidone (PVP), 0.25-0.6 W/V %; and glucose 15-35 W/V %. The metal mesh has a thickness of 0.15-0.2 mm and includes a plurality of square holes. The side length of the square holes is 2.0-3.0 mm, and the spacing between adjacent holes is 0.5-2.0 mm.

Abstract: Embodiments of a method and supplement for preventing and/or treating gastrointestinal distress, including ulcer conditions, in animals such as humans are disclosed. The supplement is in a gel or other form and comprises mastic gum and an emulsifying agent such as lecithin. The supplement may also comprise B vitamins, one or more prebiotics or probiotics, and one or more minerals as well as, pH buffers and flavoring. A disclosed method of preventing and/or treating gastrointestinal distress comprises orally dosing an animal such as a human with the supplement at least once daily.

Abstract: The present invention relates to a composition and use thereof directed towards treating various health ailments, such as skin and respiratory problems and various infections. More particularly, the present invention relates to a lime sulfur solution and use thereof, of varying percentages, directed towards improving vision and treating various skin problems and infections, such as toenail fungus, athlete's foot, jock itch, skin psoriasis, eczema, vaginal yeast infections, head or beard dandruff, respiratory infections, itching of the skin (particularly of the hands), acne (facial and/or body acne), poison ivy, insect bites, head and body lice, crabs, cuts, treating wounds infected by staff and/or MRSA (methicillin-resistant Staphylococcus aureus) bacteria, tongue thrush, ringworm, penis foreskin infections, skin tags, and is also directed towards treating various respiratory infections (such as pneumonia, chronic obstructive pulmonary disease (COPD), asthma, and Covid-19 infections).

Abstract: The present invention relates to methods for treatment or prevention of asthma, mild intermittent asthma, mild persistent asthma, moderate persistent asthma, severe persistent asthma, eosinophilic asthma, neutrophilic asthma, steroid refractory asthma, status asthmaticus, pneumonia, bronchiectasis, COPD, sarcoidosis, and lung cancer based on reducing airway hyper responsiveness, increasing pulmonary compliance, reducing lung inflammation, reducing inflammatory cell count in bronchoalveolar fluid and reducing cytokine production by administration of a mammalian ?- and/or ?-defensin.

Abstract: The present invention provides a method of treating a subject suffering from dry eye syndrome, comprising: administering to said subject a pharmaceutical composition for treating dry eye syndrome, comprising an effective amount of adipose-derived mesenchymal stem cells and the pharmaceutical composition is administered to the eye topically in the form of eye drops.

Abstract: The present invention provides a pharmaceutical composition for use in modifying scalp or skin, promoting wound healing, or modifying hair, comprising a secretion from adipose stem cells as an active ingredient, wherein 0.3 to 0.6 ?g of the secretion in terms of protein abundance per site in scalp or skin is administered.

Abstract: The present invention relates to a health functional food for inhibiting a rise of blood glucose containing coffee and tagatose.

Abstract: A device for support of an organ ex vivo comprises a chamber with a first engagement feature. A support structure includes a second engagement feature. The first and second engagement features may be engaged so that the chamber body is carried by the support structure for rotation. The chamber body comprises first and second chamber components. In a first orientation of the chamber body, the first chamber component provides support for a first surface of the organ, and the second chamber component is removable so that a second surface of the organ is exposed to manipulation from outside the chamber body. In a second orientation of the chamber body, the second chamber component provides support for the second surface of the organ, and the first chamber component is removable so that the first surface of the organ is exposed to manipulation from outside the chamber body.

Abstract: Disclosed herein are bone marrow stromal cells. The bone marrow stromal cells may express and/or secrete TGF-?I. The bone marrow stromal cells may express CXCR4. Also disclosed herein is a method of treating pain in a subject in need thereof. The method of treating may include administration of the bone marrow stromal cells to the subject. The pain may be neuropathic pain.

Abstract: Described herein is an isolated biological polysaccharide compound. The biological polysaccharide compound may be characterised by being isolated and having: glycosyl linkages comprising 1:3 linked glucopyranosyl residue of 65-95% wt and 1:6 linked glucopyranosyl residue of 5-25% wt; and a purity of 85-100% ?-D-glucan; and a molecular weight of 0.5 to 2.2 MDa; and a TNF-alpha cytokine response in a human bioassay that is at least 1.5 times greater than a negative control TNF-alpha cytokine response in a human bioassay; and being essentially insoluble in aqueous solutions. In a further aspect, methods are described of treating skin by topical application of a vehicle containing the isolated biological polysaccharide to a skin site such as a wound or burn. A method of manufacture is also described.

Abstract: Many people who suffer from anal rectal discomfort and disorders need fibrous sheet materials which are pre-moistened with a solution for improved cleansing without excessive skin irritation. The invention particularly concerns wet wipes, such as anal-rectal wipes, which comprises a solution comprising hamamelis water or witch hazel, to effectively treat anal-rectal disorders.

Abstract: A microbial fermentation composition subjected to enzymolysis, microbial fermentation and microbial transformation is prepared through extracting and hydrolyzing selected Edible and medicinal fungi Agaricus blazei, Lentinus edodes, Flammulina velutipes and ginseng of reinforcing vital energy, adding trace elements selenium, zinc and molybdenum, and fermenting and transforming by probiotics.

Abstract: A method for preparing a Rhus verniciflua Stokes extract with an increased content of fisetin, the method including adding reacting at least one catalyst selected from the group consisting of platinum, chromium, nickel, silicon, copper, and oxides of these metals, to a Rhus verniciflua Stokes extract or a concentrated Rhus verniciflua Stokes extract and conducting reaction to convert fustin contained in the Rhus verniciflua Stokes into fisetin, and a functional health food composition for preventing or ameliorating cancer, or an anticancer pharmaceutical composition for inhibiting metastasis of cancer, as a main component, containing the Rhus verniciflua Stokes extract with an increased content of fisetin, prepared by the method which provides a very safe and efficient method that is capable of preparing an extract that exhibits improved antioxidant activity and anticancer activity by increasing the content of the main functional ingredients of natural extracts, and an anticancer agent composition.

Abstract: A live tissue storage solution is formed of an aqueous culture medium including additives, inorganic salts and nutrients. The additives preferably include amino acids including but not limited to L-Arg, L-Cys, Gly, L-His, L-Ile, L-Lys, L-Leu, L-Met, L-Phe, L-Ser, L-Try, L-Try, and L-Val. The inorganic salts preferably include calcium chloride, sodium chloride, magnesium sulphate, sodium bicarbonate, sodium phosphate. The nutrients preferably include glucose, choline, folic acid, nicinamide, riboflavin, which are known to maintain cell culture. Examples include Dulbecco's Modified Eagle Medium DMEM or Minimal Essential Medium MEM with or without serum. The culture medium contains additives to reduce, inhibit, or mitigate lipid oxidation, lipotoxicy, lipid-induced responses, and lipid inflammation.

Abstract: Collagenase Clostridium histolyticum (EN3835) is a proteinase that can hydrolyze the triple-helical region of collagen under physiological conditions. EN3835 targets the collagenase structural matrix at the site of injection and does not require systemic exposure. Embodiments include methods of lysing subdermal and submucosal collagen to treat various conditions such as bladder dysfunction, esophageal stenosis, benign prostatic hyperplasia, tracheal stenosis, subglottic stenosis and scleroderma.

Abstract: A composition and method for lowing serum and plasma levels of methionine by oral administration. The composition includes a recombinant methioninase enzyme and a cofactor (pyridoxal-L-phosphate). Methods of use describe methods for treatment of cancer, including malignant melanoma, by oral administration of the methioninase composition. Methods for chronic suppressive therapy of melanoma and other cancers are described. Because reduction of plasma methionine levels is effective in treating other conditions, including diabetes and conditions associated with aging, the use of the methods described herein includes treatment of these and other conditions.